Diffusion Weighted Imaging (DWI) - ADC

Quibim

Quibim’s Diffusion Weighted Imaging (DWI) - ADC enables to automatically calculate the apparent diffusion coefficient (ADC) to quantify the diffusion of water molecules in tissues.
The suite provides information on the cellular and microstructural organization of tissues and highlights the relationship between pathological changes and the diffusion of water molecules. This suite is aimed at the characterization of tumoral processes to support early detection, diagnosis, treatment response evaluation and follow-up of patients.
Product specifications Information source: Vendor
Last updated: Nov. 19, 2021
General
Product name Diffusion Weighted Imaging (DWI) - ADC
Company Quibim
Subspeciality Abdomen, Breast, Neuro
Modality MR
Disease targeted Solid tumors, Breast cancer, Prostate cancer, Rectal cancer, Endometrial cancer, Liver cancer, Gliomas, Meningiomas, Lymphomas, Ischemic injuries
Key-features ADC Map, Histogram, Volume of smallest bvalue, values of ADC parameters
Suggested use During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand)
Data characteristics
Population Detecting changes in the microstructure of the tissue and performing early diagnosis and evaluation of treatment response
Input MRI DWI
Input format
Output One-page structured report: ADC map, histogram, volumes corresponding to smallest and largest bvalue, statistics summary
Output format DICOM Secondary Capture / PDF
Technology
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution
Trigger for analysis Automatically after drawing ROI
Processing time 1 - 10 minutes
Certification
CE
Certified, Class IIa , MDD
FDA
 No or not yet
Market presence
On market since 01-2019
Distribution channels Alma HEALTH PLATFORM
Countries present (clinical, non-research use) 10
Paying clinical customers (institutes) 5+
Research/test users (institutes) 15+
Pricing
Pricing model License
Based on Number of installations, Number of analyses
Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers Martí-Bonmatí L, Ramírez-Fuentes C, Alberich-Bayarri Á, Ruiz-Llorca C. State-of-the-art of bone marrow imaging in multiple myeloma. Curr Opin Oncol. 2015 Nov; 27(6): 540-50.